Getinge, a medical equipment and products based in Gothenburg, Sweden, today announced it has acquired 100 percent of the shares in Fraser-based Healthmark Industries Co. Inc., a leading provider of innovative instrument care and infection control consumables, for approximately $320 million.
The strategic step expands Getinge’s presence within sterile reprocessing in the U.S. and facilitates a global expansion for Healthmark.
Founded in 1969, Healthmark’s headquarters and main production facilities in Fraser are joined by a production facility in Bobigny, France. Globally, Healthmark has approximately 400 employees.
about:blank
In its fiscal year ending Oct. 31, Healthmark expects nearly $126 million in net sales, an approximate 15 percent increase over fiscal year 2022, which will translate into a material contribution to the net revenue and EBITDA of Getinge’s Surgical Workflows business area. Approximately 90 percent of Healthmark’s sales originate from the United States.
“We are excited and honored to team up with Healthmark,” says Stéphane Le Roy, president of surgical workflows at Getinge. “Together we will offer a broad range of solutions to sterile processing departments in hospitals.
“Healthmark’s position in the field of consumables for cleaning verification and packaging will be an ideal complement to our consumables, reprocessing capital equipment, and software solutions. The acquisition strengthens Getinge’s position in the infection prevention sector in the U.S., and our global customer reach in Europe and Asia will also accelerate Healthmark’s international development.”
Getinge paid the approximately $320 million on a cash and debt free basis with a normalized working capital for 100 percent of the shares in Healthmark.
Getinge expects approximately $30 million in gradual net synergies (revenues and costs) for the coming five years. Based on expected calendar year 2023 EBITDA, the purchase price implies an EBITDA multiple of 17.1x or 15.5x net of the present value of tax benefits.
According to expectations for calendar year 2024 including net synergies, the purchase price implies an EBITDA multiple of 14.6x or 13.2x net of the present value of tax benefits. The company also anticipates a positive contribution on reported earnings per share, starting in 2026.
Getinge expects to have fully integrated Healthmark by the end of 2024, and anticipates no material integration costs in 2023 and 2024.
“We are pleased with Healthmark being integrated into the Getinge family,” says Mark Basile, president and CEO of Healthmark. “This combination makes sense due to the minimal overlap in our product portfolios. By bringing together our strengths, we are well positioned to better serve our customers, gain greater control over our supply chain and finished products, and expand our reach outside the United States.”
The acquisition is not expected to have a material impact on Getinge’s operating profit and earnings per share in 2023.
The statutorily required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR) has passed. The transaction is closed and is not subject to further regulatory approvals or waiting periods, Getinge states.
Source : DB
